Merrimack (MACK) Onivyde Labeling Appears as Expected, Says Mizuho Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Merrimack Pharmaceuticals (MACK) Weakness Creates Buying Opportunity, Mizuho Securities Says
October 23, 2015 6:51 AM EDTWeakness in Merrimack Pharmaceuticals (NASDAQ: MACK) following FDA approval of ONIVYDE presents a buying opportunity, according to Eric Criscuolo of Mizuho Securities. The firm reiterated an Outperform rating and price target of $16.
Criscuolo commented, "We think the 13% decline following news of ONIVYDE approval... More
Merrimack Pharma (MACK) to Resume Trading at 1:40 PM EDT
October 22, 2015 1:32 PM EDTMerrimack Pharma (NASDAQ: MACK) to Resume Trading at 1:40 PM EDT
... MoreFDA Approves Merrimack Pharma's (MACK) ONIVYDE
October 22, 2015 11:32 AM EDT(Updated - October 22, 2015 11:35 AM EDT)
The U.S. Food and Drug Administration today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.
According to the National Cancer Institute, there will be 48,960 new cases of pancreatic cancer diagnosed in the U.S. in 2015, and nearly the same number of deaths caused by the disease (40,560). Pancreatic cancer can be difficult to diagnose early and treatment options are limited, especially when the disease has spread to other parts of the body (metastatic... More
Merrimack Pharma (MACK) Halted, News Pending
October 22, 2015 11:23 AM EDTMerrimack Pharma (NASDAQ: MACK) Halted, News Pending
... MorePharmaEngine Announces Taiwan FDA Approval of ONIVYDE to Treat Metastatic Pancreatic Cancer (MACK)
October 22, 2015 9:08 AM EDTPharmaEngine, Inc. (TWO: 4162) announced that the Taiwan Food and Drug Administration (TFDA) has approved ONIVYDETM (irinotecan liposome injection) in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. ONIVYDE is not indicated for use as a single agent. The TFDA is the first regulatory authority in the world granting the approval of ONIVYDE.
"We are very grateful that the TFDA granted the regulatory approval in such a rapid pace, especially the accelerated efforts made by the Center of Drug Evaluation (CDE) and the... More
